AU2003204088A1 - Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them - Google Patents

Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them

Info

Publication number
AU2003204088A1
AU2003204088A1 AU2003204088A AU2003204088A AU2003204088A1 AU 2003204088 A1 AU2003204088 A1 AU 2003204088A1 AU 2003204088 A AU2003204088 A AU 2003204088A AU 2003204088 A AU2003204088 A AU 2003204088A AU 2003204088 A1 AU2003204088 A1 AU 2003204088A1
Authority
AU
Australia
Prior art keywords
monoclonal antibodies
compositions containing
malignant tumors
active immunotherapy
idiotypic monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2003204088A
Other versions
AU2003204088B2 (en
Inventor
Irene Beausoleil Delgado
Alexis Perez Gonzalez
Ana Maria Vazquez Lopez
Gumersinda Bombino Lopez
Rolando Perez Rodriguez
Eladio Iglesias Sierra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Immunologia Molecular
Original Assignee
Centro de Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU10199/99A external-priority patent/AU1019999A/en
Application filed by Centro de Immunologia Molecular filed Critical Centro de Immunologia Molecular
Priority to AU2003204088A priority Critical patent/AU2003204088B2/en
Priority claimed from AU2003204088A external-priority patent/AU2003204088B2/en
Publication of AU2003204088A1 publication Critical patent/AU2003204088A1/en
Application granted granted Critical
Publication of AU2003204088B2 publication Critical patent/AU2003204088B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

AU2003204088A 1997-10-21 2003-05-08 Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them Expired AU2003204088B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003204088A AU2003204088B2 (en) 1997-10-21 2003-05-08 Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU119/97 1997-10-21
AU10199/99A AU1019999A (en) 1997-10-21 1998-10-21 Anti-idiotype monoclonal antibodies, their use in active immunotherapy of malignant tumors and compositions containing them
AU2003204088A AU2003204088B2 (en) 1997-10-21 2003-05-08 Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU10199/99A Division AU1019999A (en) 1997-10-21 1998-10-21 Anti-idiotype monoclonal antibodies, their use in active immunotherapy of malignant tumors and compositions containing them

Publications (2)

Publication Number Publication Date
AU2003204088A1 true AU2003204088A1 (en) 2003-06-12
AU2003204088B2 AU2003204088B2 (en) 2005-10-20

Family

ID=39367686

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003204088A Expired AU2003204088B2 (en) 1997-10-21 2003-05-08 Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them

Country Status (1)

Country Link
AU (1) AU2003204088B2 (en)

Similar Documents

Publication Publication Date Title
AU1332099A (en) Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
AU5414996A (en) Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma
PL335348A1 (en) Compounds for use in prostatic carcinoma immunotherapy and methods using them
AU2472400A (en) CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
AU1704099A (en) Monoclonal human natural antibodies
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
AU4397297A (en) Antibody against human parathormone related peptides
AU4824297A (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
AU1462300A (en) Human pan-hcv human monoclonal antibodies
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
EP0673638A3 (en) Hair cosmetic composition containing an antibody.
AU4119397A (en) Novel combination preparations and their use in immunodiagnosis and immunotherapy
AU4373197A (en) Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
AU1538497A (en) Anti-gp46 antibodies and fragments thereof and their use
AU2408397A (en) Ob protein receptor genes and use of the same
AU9689398A (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
AU2539697A (en) Anti-idiotypic antibody vaccines
AU1615701A (en) Compositions and methods for regulating tumor-associated antigen expression
NZ501742A (en) Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
AU7572198A (en) Tumor-associated antigen
SI1027375T1 (en) Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them
AU9018598A (en) Prognostic compositions for prostate cancer and methods of use thereof
AU2003204088A1 (en) Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them
AU2003204129A1 (en) Anti-idiotype monoclonal antibodies, their use in active immunotherapy of malignant tumors and compositions containing them